Streetbeat News

PKBO

Peak Bio Inc

Employees

Industry

Research and Development in Biotechnology

Open

0.05

Mkt cap

532K

Volume

1.9K

High

0.07

P/E Ratio

-0.16

52-wk high

0.27

Low

0.02

Div yield

N/A

52-wk low

0.00

Akari Therapeutics and Peak Bio have announced a portfolio prioritization plan following their merger. The plan focuses on advancing Peak's ADC cancer therapeutic platform and Akari's PAS-nomacopan for Geographic Atrophy. Additionally, Akari Therapeutics has announced leadership changes.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 12:08 pm

Akari Therapeutics and Peak Bio have announced a merger of equals. The exchange terms suggest that Akari shareholders and Peak stockholders will each own approximately 50% of the combined company.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:03 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.